NCT06192979 2026-03-09
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Peking University People's Hospital
Phase NA Recruiting
Clinical Trials
10 trialsNCT06203145 2024-01-12
A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM
Peking University First Hospital
Phase NA Unknown
NCT02037256 2021-05-10
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT03401372 2021-02-23
BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients
Peking Union Medical College Hospital
Phase NA Completed
NCT01383759 2020-04-07
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT03390387 2020-02-05
ALL-MB 2015
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase NA Unknown
NCT00789256 2018-10-24
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Dartmouth-Hitchcock Medical Center
Phase NA Completed
NCT00772668 2017-12-11
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
University of Miami
Phase NA Terminated
NCT00135187 2012-02-07
Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma
University of Michigan Rogel Cancer Center
Phase NA Completed
NCT00569868 2011-08-12
UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma
University of Arkansas
Phase NA Completed